Complete Table of Contents 2017

Publication
Article

The table of contents for the latest issue of the journal ONCOLOGY: Perspectives on the Treatment of Hematologic and Solid Malignancies.

August 2017 Table of Contents

Volume 31 | Number 8
REVIEW ARTICLES

Changing Treatment Paradigms for Brain Metastases From Melanoma-Part 1: Diagnosis, Prognosis, Symptom Control, and Local Treatment Vyshak Alva Venur, Pauline Funchain, Rupesh Kotecha, et al

Circulating Tumor DNA as a Liquid Biopsy: Current Clinical Applications and Future DirectionsKimberly M. Komatsubara and Adrian G. Sacher

How an Expert Approaches It

Management of Castration-Resistant, Taxane-Resistant Prostate CancerTomasz M. Beer

Comorbidity Consult

Management of Sleep-Wake Disturbances Comorbid With CancerAnn M. Berger, Ellyn E. Matthews, and Ashley M. Kenkel

Point/Counterpoint

POINT: Should Radiation Therapy After Surgery for Ductal Carcinoma In Situ Be Standard Practice?Camille Berriochoa, Carisa Bohnak, Nicole Chahine, and Chirag Shah

COUNTERPOINT: Should Radiation Therapy After Surgery for Ductal Carcinoma In Situ Be Standard Practice?William C. Wood

Q&A

Fay Hlubocky on Recognizing and Addressing Clinician Burnout

Recent Videos
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
Related Content